(Q44654377)

5 December 2017

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide (English)

1 reference

5 December 2017

1 reference

1 reference

Mark Alastair Boyd

1

0 references

Kiat Ruxrungtham

4

object named as

Kiat Ruxrungtham

1 reference

5 December 2017

Xiaoping Zhang

2

1 reference

5 December 2017

Albert Dorr

3

1 reference

5 December 2017

Stanley Kolis

5

1 reference

5 December 2017

Keith Nieforth

6

1 reference

5 December 2017

Tosca Kinchelow

7

1 reference

5 December 2017

Neil Buss

8

1 reference

5 December 2017

Indravadan H Patel

9

1 reference

5 December 2017

1 December 2003

1 reference

The Journal of Clinical Pharmacology

5 December 2017

1 reference

5 December 2017

43

1 reference

5 December 2017

12

1 reference

5 December 2017

1382-1391

1 reference

Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.

5 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

HIV fusion and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Pharmacokinetic drug interactions with rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Rifampin and rifabutin drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Nelfinavir. A review of its therapeutic efficacy in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Pharmacokinetic factors in the modern drug treatment of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

The influence of sex on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Possible clinically significant interaction of itraconazole plus rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Renal allograft dysfunction associated with rifampin-tacrolimus interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

[Influence of rifampicin on antihypertensive effects of dihydropiridine calcium-channel blockers in four elderly patients]

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003259220

21 January 2018

Identifiers

DOI

10.1177/0091270003259220

1 reference

5 December 2017

1 reference